Syndax Pharmaceuticals SNDX Business Segments — Other Operating Income Expense Net

Similar metrics at other companies

ANABBiopharma Company — Other Nonoperating Income Expense

-$1K+85.7%

PFEBiopharma — Other Nonoperating Income (Expense)

$116M+48.7%

MLTXOther Nonoperating Income

$3.21M-54.8%

ANABBiopharma Company — Nonoperating Income Expense

$2.33M-43.0%

BDXBioPharma Systems — Other Operating Income

$0—

OGNOther Operating And Nonoperating Income (Expense)

$96M+900%

Questions, answered.

What is Syndax Pharmaceuticals's business segments — other operating income expense net?

Syndax Pharmaceuticals (SNDX) reported business segments — other operating income expense net of $186K in Q1 2026.

How has Syndax Pharmaceuticals's business segments — other operating income expense net changed year-over-year?

Syndax Pharmaceuticals's business segments — other operating income expense net decreased by 15.8% year-over-year, from $221K to $186K.

What is the long-term trend for Syndax Pharmaceuticals's business segments — other operating income expense net?

Over 3 years (2022 to 2025), Syndax Pharmaceuticals's business segments — other operating income expense net has grown at a 59.5% compound annual growth rate (CAGR), from $316K to $1.28M.

What does business segments — other operating income expense net mean?

This metric captures miscellaneous operating income and expenses that are not directly attributable to core product sales, research, or general administrative functions within the business segment. It includes non-recurring or peripheral items such as gains or losses from asset disposals, legal settlements, or other ancillary operational activities. Tracking this figure allows stakeholders to isolate the impact of non-core events on the segment's operational performance.